
DOC Updates
DOC Updates is a monthly podcast that presents and discusses the latest clinically relevant articles in the field of diabetes research and care, including the American Diabetes Association's three science and health jour...
Insights from recent episode analysis
On the show
- Aaron King1 ep
- Janet McGill1 ep
- Dr. Juan Frias1 ep
Also: Timothy Dall, MS, Melanie R. Jay, MD, Catherine Ferguson, MA, Anna Kahkoska, Joshua Niznik, Esben Thyssen Vestergaard, Leigh Perreault, Mikhail Kosiborod, John Buse, Payal Kohli, Jay Shubrook, Susan Kuchera, Jamie Almondoz, MD, Nihar Desai, Katherine R. Tuttle, Alexander Turchin, Dr. Minesh Rajpal
Audience Interest
Podcast Focus
Publishing Consistency
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Total monthly reach
Based on 1 signal.
Built from
By chart position
- 🇺🇸United States · MedicineHOME#1339.0K to 48K
- 🇮🇳India · Medicine#277.2K to 38K
- 🇧🇷Brazil · Medicine#346.2K to 33K
- 🇹🇭TH · Medicine#93.8K to 20K
- 🇯🇵Japan · Medicine#481.6K to 8.5K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
33K to 174K🎙 Weekly cadence·100 episodes·Last published 3d ago - Monthly Reach
Unique listeners across all episodes (30 days)
66K to 347K🇺🇸27%🇮🇳22%🇧🇷19%+10 more - Active Followers
Loyal subscribers who consistently listen
36K to 191K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 11/17/26 | What's Next—Hypercortisolism in Uncontrolled Diabetes and Resistant Hypertension: When and How to Test for Excess Cortisol | Once thought to be rare, an emerging understanding shows that hypercortisolism plays a significant role in both diabetes and hypertension. In this special episode of DOC Updates, Neil Skolnik explores the downstream consequences of undiagnosed hypercortisolism and how to make an effective diagnosis. This special episode is sponsored with support from Corcept. Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Pamela Kushner, MD, Clinical Professor of Family Medicine at the University of California at Irvine and Medical Director of the Kushner Wellness Center in Los Angeles. Vivian Fonseca, MD, Professor of Medicine and Pharmacology Assistant Dean for Clinical Research Tullis Tulane Alumni Chair in Diabetes Chief, Section of Endocrinology Tulane University Health Sciences Selected References: Buse, et al. Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes. Diabetes Care 20 November 2025; 48 (12): 2012–2020. https://doi.org/10.2337/dc24-2841 DeFronzo et al. Inadequately Controlled Type 2 Diabetes and Hypercortisolism: Improved Glycemia With Mifepristone Treatment. Diabetes Care 20 November 2025; 48 (12): 2036–2044. https://doi.org/10.2337/dc25-1055 MOMENTUM: Hypercortisolism Present in 1-in-4 with Resistant Hypertension. HCP Live, March 2026 | 31m 33s | ||||||
| 11/10/26 | Continuous Ketone Monitoring in People with Diabetes—Part 2 | With over 200,000 hospital admissions each year from diabetic ketoacidosis, new continuous ketone monitoring systems can address a critical care gap. In the second part of our special series, Neil Skolnik explores the value of this new technology and delves into specific case studies. This special episode is sponsored with support from Abbott. Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Jennifer Goldman, PharmD, CDCES, BC-ADM, FCCP, Professor of Pharmacy Practice, Massachusetts College of Pharmacy and Heath Sciences, Boston, Mass.; Clinical pharmacist and the Clinical Director of Cardiometabolic Services at Well Life Medical in Peabody, MA References: Hyperglycemic Crises in Adults With Diabetes: A Consensus Report. Diabetes Care 2024;47:1257–1275 doi.org/10.2337/dci24-0032 Continuous ketone monitoring: Exciting implications for clinical practice. Diabetes Obesity, and Metabolism. 2024; 26 (Suppl. 7): 47-58. doi.org/10.1111/dom.15921 Continuous ketone monitoring for people with diabetes: international expert recommendations on the application of a new technology. The Lancet Diabetes & Endocrinology. 2026; 14:82 doi.org/10.1016/S2213-8587(25)00331-6 | 28m 22s | ||||||
| 11/3/26 | What's Next: CKD in People with Diabetes—A Case-Based Discussion | There are multiple options now for slowing the progression of chronic kidney disease. In part 5 of our special series, host Dr. Neil Skolnik takes a case-based approach to explore treatment options for CKD. This special episode is sponsored with support from Bayer. Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Holly Kramer, MD, MPH, Professor of Public Health Sciences and Medicine in the Division of Nephrology and Hypertension at Loyola University in Chicago, Illinois Selected References: Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026. The American Diabetes Association's Standards of Care 2026, Diabetes Care 2026;49 (Supplement_1):S246–S260 doi.org/10.2337/dc26-S011 Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med 2020;383:2219-2229 doi.org/10.1056/NEJMoa2025845 Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2020;383:1436-1446 doi.org/10.1056/NEJMoa2024816 Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med 2024;391:109-121 doi.org/10.1056/NEJMoa2403347 Diabetic Nephropathy: Update on Pillars of Therapy Slowing Progression. Diabetes Care 2023;46(9):1574–1586 doi.org/10.2337/dci23-0030 The Kidney Failure Risk Equation - kidneyfailurerisk.com | 42m 49s | ||||||
| 10/29/26 | CGMs & Non-Insulin-Treated T2D, Islet Autoantibody Screening & T1D, Semaglutide CVD Risk Reduction, and more! | Welcome to the latest episode (November 2026) of DOC Updates, where every month Neil Skolnik, MD and John Russell, MD review the most important articles on diabetes, obesity, and cardiometabolic disease. This month on DOC Updates: Oser, et al. Continuous Glucose Monitoring in Non–Insulin-Treated Type 2 Diabetes. New England Journal of Medicine. October 2026; doi.org/10.1056/NEJMoa2608571 Islet autoantibody screening identifies early-stage type 1 diabetes across Europe, Need-To-Know Institute press release Yang, et al. Sodium-Glucose Cotransporter 2 Inhibitor Use and Levels of Hemoglobin, Markers of Iron Metabolism, and Erythropoiesis. JAMA. Published online October 2026. doi.org/10.1001/jama.2026.19921 Jastreboff, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. New England Journal of Medicine. September, 2026. doi.org/10.1056/NEJMoa2604169 Bellido, et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. The Lancet. Volume 408, Issue 10563. doi.org/10.1016/S0140-6736(26)01861-1 Colhoun, et al. Semaglutide and cardiovascular risk reduction: a mediation analysis of the SELECT trial. European Heart Journal. 2026; ehag524, doi.org/10.1093/eurheartj/ehag524 Garvey, et al. Petrelintide, a human amylin analogue for the treatment of obesity (ZUPREME 1): a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet Diabetes & Endocrinology, 2026; 14, 914-926. doi.org/10.1016/S2213-8587(26)00213-5 Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John J. Russell, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Chair-Department of Family Medicine, Abington Jefferson Health DOC Updates is a monthly podcast that presents and discusses the latest clinically relevant articles from the American Diabetes Association's three science and medical journals—Diabetes, Diabetes Care, and Diabetes, Obesity, and CardioMetabolic CARE. Intended for practicing physicians and health care professionals, DOC Updates discusses how the latest research is relevant in clinical practice. For information about the American Diabetes Association's scholarly journals, visit diabetesjournals.org. For more about this podcast, click here. | 31m 52s | ||||||
| 10/26/26 | What's Next—Amylin-based Therapies | We are entering an era of choice in terms of diabetes and obesity therapies. Choice is good, but having a keen understanding of each medication is crucial to avoid being overwhelmed. In this special episode of DOC Updates, host Dr. Neil Skolnik explores the latest amylin-based therapies. This special episode is sponsored with support from Novo Nordisk. Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Juan Pablo Frias, MD, Medical Director and Principal Investigator, Los Angeles Institute for Metabolic Research, Adjunct Professor of Medicine at Charles Drew University of Medicine and Science Selected References: Garvey, et al. "Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity," N Engl J Med 2025;393:635-647 doi.org/10.1056/NEJMoa2502081 Aroda V, Buzzetti R, Dalskov S et al. "Efficacy and safety of once-weekly cagrilintide–semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study," The Lancet Diabetes & Endocrinology, 2026; 14, 649-661 doi.org/10.1016/S2213-8587(26)00126-9 | 27m 31s | ||||||
| 10/13/26 | Variability in Autoantibody Ordering Patterns & Diabetes Misclassification and Determinants of Cognitive Change Over 1 Year in Older Adults With T1D | With the launch of a new journal, the American Diabetes Association (ADA) is also launching a brand new podcast: The Points of CARE, the official podcast of Diabetes, Obesity, and CardioMetabolic CARE. Join hosts Richard Beaser, MD and Jane Reusch, MD, as they highlight key research findings, clinical implications, and emerging themes across diabetes, obesity, and cardiometabolic health through interviews with journal authors and subject-matter experts. 2:20 Our hosts speak with Klara Klein, MD, PhD, assistant professor of medicine at the University of North Carolina School of Medicine in Chapel Hill, North Carolina, and Marie Claire Abram, attending physician at Maine Health Medical Center in Portland, Maine. Their article, "Variability in Autoantibody Ordering Patterns Suggests Potential for Diabetes Misclassification," is available at doi.org/10.2337/doc26-0071. 13:10 Next, Jane introduces Miranda Zuniga-Kennedy, MS, a clinical psychology graduate student at WSU. Her article, "Determinants of Cognitive Change Over 1 Year in Older Adults With Type 1 Diabetes," is available at doi.org/10.2337/doc26-0069. 25:05 Finally, Richard and Jane highlight some of their favorite articles from the September-October issue. Chae, et al. "Physical Activity Patterns in Adults Taking Glucagon-Like Peptide-1 Receptor Agonists: An All of Us Cross-Sectional Study," doi.org/10.2337/doc26-0062 Descarpentrie, et al. "School Meal Participation, Overall Dietary Intake, and Prediabetes Prevalence Among U.S. Adolescents: Insights From the National Health and Nutrition Examination Survey (2017–2023)," doi.org/10.2337/doc26-0084 Bannuru, et al. "Comparative Effectiveness of Continuous Glucose Monitoring Versus Blood Glucose Monitoring in Pregnancy With Diabetes: Systematic Review and Meta-analysis With Trial Sequential Analysis," doi.org/10.2337/doc26-0018 March, et al. "Implementation of Diabetes Care Coordination in Schools Across Pediatric Centers in the T1D Exchange Quality Improvement Collaborative," doi.org/10.2337/doc26-0110 Adel, et al. "Virtual Diabetes Optimization Program (VDOP) for Veterans With Uncontrolled Diabetes," doi.org/10.2337/doc26-0020 Smith-Morris, et al. "Culinary Medicine and Medical Nutrition Therapy Interventions to Improve Glycemic Control in Type 2 Diabetes: A Pragmatic Trial During the COVID-19 Pandemic," doi.org/10.2337/doc26-0048 To learn more about Diabetes, Obesity, and CardioMetabolic CARE please visit diabetesjournals.org/docm-care. Thank you for listening, and don't forget to subscribe. | 46m 29s | ||||||
| 10/13/26 | Hypertension Part 3—Advanced Hypertension Management: Challenging Cases | Now it is time to look at some specific examples of hypertension. In the final installment of this special three-part series, Dr. Neil Skolnik dives into case studies which are emblematic of typical patient profiles, but ones which also present unique challenges. This series is sponsored with support from AstraZeneca. Please listen to the episodes by clicking on the podcast player below or by freely subscribing to DOC Updates via Apple Podcasts, Amazon Music, Spotify, or your preferred podcast platform. Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Raymond R. Townsend, MD, Professor of Medicine, Department of Internal Medicine/Renal, University of Pennsylvania School of Medicine Susan K. Kuchera, MD, Program Director of the Jefferson Health Abington Family Medicine Residency Program and Clinical Associate Professor of Family and Community Medicine at the Sidney Kimmel Medical College of Thomas Jefferson University Selected references: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee. Hypertension 2025; 82(10) Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 2016;387:957 Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension. N Engl J Med 2025;393:1363-74. DOI: 10.1056/NEJMoa2507109 Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism, 2025, 00, 1–43 https://doi.org/10.1210/clinem/dgaf284 A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med 2015;373:2103-2116 | 35m 31s | ||||||
| 10/6/26 | Beyond Diabetes and Obesity: Expanding Applications of Incretin Biology | You know how GLP-1s impact diabetes and weight loss. But what about coronary disease treatment and prevention? Liver disease? Heart failure? Osteoarthritis? Sleep apnea? In this special episode, Dr. Neil Skolnik covers it all, exploring what we do—and do not—know about the expanding scope of GLP-1-based therapies. This special episode is sponsored with support from Lilly. Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Donna Ryan, MD, professor emeritus at the Pennington Biomedical Research Center in Baton Rouge, Louisiana and former president of both the Obesity Society and the World Obesity Federation References: The expanding landscape of GLP-1 medicines. Nature Medicine volume 32, pages 47–57 (2026) doi.org/10.1038/s41591-025-04124-5 Weight-loss-independent actions of GLP-1 medicines. Cell Metabolism, 38, 1535-1539 doi.org/10.1016/j.cmet.2026.07.006 Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med 2023;389:2221-2232 doi.org/10.1056/NEJMoa2307563 | 32m 05s | ||||||
| 9/24/26 | T2D & Bone Density, Microarchitecture, & Strength; Early Weight Loss, Glucose Tolerance, & Long-Term Mortality/CVD Risk; and more! | Welcome to the latest episode (October 2026) of DOC Updates, where every month Neil Skolnik, MD and John Russell, MD review the most important articles on diabetes, obesity, and cardiometabolic disease. This month on DOC Updates: Zoungas et al; Atorvastatin, Cardiovascular Events, and Disability-free Survival in Older Adults. New England Journal of Medicine, 28 August 2026; doi.org/10.1056/NEJMoa2607314 Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD), press release N. Kruger, et al; Tirzepatide and the risk of atherosclerotic cardiovascular events: population based cohort study. BMJ 2026; 394 doi.org/10.1136/bmj-2026-100011 Dufour, et al; Type 2 Diabetes and Longitudinal Changes in Cortical and Trabecular Bone Density, Microarchitecture, and Strength: The Framingham Study. Diabetes Care 2026; dc260846. doi.org/10.2337/dc26-0846 He, et al; Early Weight Loss in Impaired Glucose Tolerance Is Associated With Reduced Long-term Mortality and Cardiovascular Risk: The Da Qing Diabetes Prevention Outcome Study. Diabetes Care 2026; dc260689. doi.org/10.2337/dc26-0689 Leavens ELS, Pebley K, Smith TT, et al; Nicotine E-Cigarettes for Cigarette Smoking Cessation: Recommendations to US-Based Clinicians. JAMA. 2026;336(9):783–790. doi.org/10.1001/jama.2026.13087 Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John J. Russell, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Chair-Department of Family Medicine, Abington Jefferson Health DOC Updates is a monthly podcast that presents and discusses the latest clinically relevant articles from the American Diabetes Association's three science and medical journals—Diabetes, Diabetes Care, and Diabetes, Obesity, and CardioMetabolic CARE. Intended for practicing physicians and health care professionals, DOC Updates discusses how the latest research is relevant in clinical practice. For information about the American Diabetes Association's scholarly journals, visit diabetesjournals.org. For more about this podcast, click here. | 32m 44s | ||||||
| 9/14/26 | Sarcopenic Obesity & T2D, Cumulative BMI Burden From Childhood to Adulthood & Risk of Metabolic Multimorbidity, and more! | Welcome to the latest episode (September 2026) of DOC Updates, where every month Neil Skolnik, MD and John Russell, MD review the most important articles on diabetes, obesity, and cardiometabolic disease. This month on DOC Updates: Diaz KM, Murdock ME, Serafini MA, et al. Evaluating movement breaks as a public health strategy to mitigate the harms of prolonged sitting: a large-scale pragmatic intervention. British Journal of Sports Medicine 2026;60:1208-1217. Chorniy, et al. Progression to Diabetes by Adults With Prediabetes Who Use the National Diabetes Prevention Program: A Natural Experiment. Diabetes Care 20 August 2026; 49 (9): 1576–1584. doi.org/10.2337/dc25-2485 Harnois-Leblanc, et al. Genetic Determinants of Macronutrient Intake Are Associated With Specific Food Intake in Youth: A Cohort Study Across Childhood and Adolescence. Diabetes Care 20 August 2026; 49 (9): 1645–1653. doi.org/10.2337/dc25-2975 Guan, et al. Sarcopenic Obesity and Risk of Incident Type 2 Diabetes: A Prospective Cohort Study and Landmark Analysis From the UK Biobank. Diabetes Care 20 August 2026; 49 (9): 1663–1668. doi.org/10.2337/dc26-0797 Guo, et al. Life Course Cumulative BMI Burden From Childhood to Adulthood and Risk of Metabolic Multimorbidity: A 36-Year Prospective Cohort Study. Diabetes Care 20 August 2026; 49 (9): 1567–1575. doi.org/10.2337/dc25-2889 Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John J. Russell, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Chair-Department of Family Medicine, Abington Jefferson Health DOC Updates is a monthly podcast that presents and discusses the latest clinically relevant articles from the American Diabetes Association's three science and medical journals—Diabetes, Diabetes Care, and Diabetes, Obesity, and CardioMetabolic CARE. Intended for practicing physicians and health care professionals, DOC Updates discusses how the latest research is relevant in clinical practice. For information about the American Diabetes Association's scholarly journals, visit diabetesjournals.org. For more about this podcast, click here. | 24m 37s | ||||||
| 9/8/26 | hypertensionaldosterone+4 | Payal Kohli | American Diabetes AssociationSidney Kimmel Medical College+7 | — | hypertensionaldosterone+5 | AstraZeneca | 39m 38s | ||
| 9/3/26 | Metabolic DysfunctionLiver Disease+3 | Jay ShubrookSusan Kuchera | American Diabetes AssociationClinical Care Pathway for the Risk Stratification and Management of Patients With Metabolic Dysfunction–Associated Steatotic Liver Disease+2 | — | MASHMASLD+4 | Lilly | 22m 38s | ||
| 8/24/26 | weight lossweight maintenance+3 | Jamie Almondoz, MD | American Board of Obesity Medicine (ABOM)University of Texas Southwestern Medical Center+2 | — | weight maintenanceobesity+3 | Lilly | 32m 04s | ||
| 8/17/26 | chronic kidney diseasetype 1 diabetes+4 | Nihar Desai | American Diabetes AssociationChronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026+2 | — | chronic kidney diseasetype 1 diabetes+8 | Bayer | 33m 00s | ||
| 8/10/26 | SGLT2 inhibitorschronic kidney disease+4 | Katherine R. TuttleAlexander Turchin | American Diabetes AssociationDiabetes, Obesity, and CardioMetabolic CARE+2 | — | SGLT2CKD+5 | — | 35m 49s | ||
| 8/10/26 | FinerenoneAlbuminuria+5 | — | American Diabetes AssociationAnn Intern Med+2 | — | FinerenoneAlbuminuria+5 | — | 32m 19s | ||
| 8/6/26 | hypertensionhigh blood pressure+3 | Dr. Minesh Rajpal | American College of CardiologyAmerican Heart Association+1 | — | hypertensionhigh blood pressure+3 | AstraZeneca | 33m 38s | ||
| 7/30/26 | diabetes researchclinical practice+3 | Alice Cheng, MDKirk Habegger, PhD+3 | American Diabetes Association | New Orleans | diabetesresearch+5 | — | 44m 41s | ||
| 7/24/26 | Lipoprotein(a)cardiovascular disease+3 | Michael Wilkinson | American Heart AssociationNational Lipid Association+2 | University of California San Diego HealthSidney Kimmel Medical College+2 | Lp(a)cardiovascular risk+3 | Lilly | 34m 06s | ||
| 7/17/26 | once-weekly insulinsdiabetes management+3 | Aaron King | American Diabetes AssociationWeekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin+1 | — | once-weekly insulindiabetes+3 | Novo | 25m 40s | ||
| 7/7/26 | chronic kidney diseasetype 1 diabetes+4 | Janet McGill | American Diabetes AssociationChronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026+2 | — | CKDtype 1 diabetes+6 | Bayer | 28m 18s | ||
| 6/30/26 | CagriSemaRetatrutide+4 | — | American Diabetes AssociationEfficacy and safety of once-weekly cagrilintide–semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study+4 | — | CagriSemaRetatrutide+6 | — | 34m 30s | ||
| 6/25/26 | cardiometabolic diseasemedications+3 | Dr. Juan Frias | American Diabetes AssociationLos Angeles Institute for Metabolic Research+2 | Thomas Jefferson University | cardiometabolic medicationsdiabetes+3 | Lilly | 25m 10s | ||
| 6/24/26 | obesity treatmenteconomic costs+4 | Timothy Dall, MSMelanie R. Jay, MD+1 | American Diabetes AssociationWeill-Cornell Medical College+4 | — | DiabetesObesity+5 | — | 29m 56s | ||
| 6/10/26 | patient portal messagesolder adults+4 | Anna KahkoskaJoshua Niznik+1 | American Diabetes AssociationQualitative Analysis of Patient Portal Messages From Older Adults With Type 2 Diabetes+1 | — | diabetespatient portal+5 | — | 38m 08s | ||
| 6/2/26 | food coloring additivestype 2 diabetes+5 | — | American Diabetes AssociationFood Coloring Additives and Incidence of Type 2 Diabetes in the NutriNet-Santé Prospective Cohort+5 | — | type 2 diabetesfood coloring+5 | — | 38m 41s | ||
| 5/29/26 | obesity careprimary care+3 | Leigh Perreault | American Diabetes AssociationImplementation and effectiveness of a care process to prioritize weight management in primary care: a stepped-wedge cluster-randomized trial | Sidney Kimmel Medical College, Thomas Jefferson UniversityUniversity of Colorado Denver School of Medicine, Aurora, CO | obesityweight gain+3 | Lilly | 30m 00s | ||
| 5/26/26 | ObesityCardiometabolic diseases+3 | Mikhail Kosiborod | American Diabetes AssociationAmerican Heart Association+1 | — | obesitycardiometabolic diseases+6 | AstraZeneca | 33m 31s | ||
| 5/19/26 | hypercortisolismdiabetes+3 | John Buse | American Diabetes AssociationDiabetes Care | — | hypercortisolismdiabetes+5 | Corcept | 27m 06s | ||
Showing 29 of 100
Pitch Fit is a Pro feature
See how bookable this show is for guests, which brands already advertise, the per-episode ad value, and the best-fit guest and sponsor profile. The numbers are blurred on the free plan.
How readily this show books outside guests like you.
How proven this show is for host-read sponsorships.
For Guests
ProFor Advertisers
ProUpgrade to Pro to unlock guest cadence, sponsor categories, fit scores, and per-episode ad value for this show.
Similar Audience Demographics
Podcasts that attract a similar listener profile
Chart history for DOC Updates
Peaked at #9 in TH, top 10 in 1 of 26 tracked markets, currently #9 in TH.
| Market | Genre | Peak | Current | Trend |
|---|---|---|---|---|
| TH | — | #9 | #9 | — |
| SA | — | #24 | #24 | — |
| IS | — | #26 | #26 | — |
| India | — | #27 | #27 | — |
| KE | — | #27 | #27 | — |
| Brazil | — | #34 | #34 | — |
| CO | — | #34 | #34 | — |
| AE | — | #36 | #36 | — |
| GR | — | #45 | #45 | — |
| Japan | — | #48 | #48 | — |
| Ireland | — | #56 | #56 | — |
| TH | — | #71 | #71 | — |
| South Korea | — | #77 | #77 | — |
| RO | — | #87 | #87 | — |
| IL | — | #101 | #101 | — |
| Norway | — | #109 | #109 | — |
| VN | — | #111 | #111 | — |
| PE | — | #113 | #113 | — |
| Mexico | — | #116 | #116 | — |
| TW | — | #117 | #117 | — |
Chart Positions
26 placements across 23 markets.
Chart Positions
26 placements across 23 markets.